View Archive

Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669.

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca and Daiichi-Sankyo, Inc.

Onco-Nurse Academy™: Evolving HER2 Treatment Approaches Across Tumor Types

Onco-Nurse Academy™: Evolving HER2 Treatment Approaches Across Tumor Types

Thursday, April 22, 2021

Live Interactive Webcast!
5:00 PM – 6:30 PM ET


HER2 amplification has been increasingly recognized as a frequent abnormality in not only lung and gastric cancer, but also gastroesophageal and colorectal cancers. HER2 genetic testing is essential for determining which patients will benefit from treatment with HER2-targeted agents; however, HER2 testing guidelines vary among the different tumor types. The utilization of HER2-targeted agents for the treatment of these cancers has increased. Novel HER2-targeted agents include the monoclonal antibodies trastuzumab, pertuzumab, and margetuximab; the antibody-drug conjugates ado-trastuzumab emtansine and fam-trastuzumab deruxtecan; as well as the tyrosine kinase inhibitors lapatinib, neratinib, and tucatinib. Importantly, each of these drug families is associated with different adverse events (AEs) and, therefore, requires individualized monitoring as well as mitigation and treatment strategies.

This live webcast is specifically designed to educate and empower nursing professionals who provide health care to patients with breast, gastrointestinal, colorectal, and lung cancer. It will feature expert faculty sharing data and clinical insights on the role and mechanistic activity of HER2-targeted therapies used to treat these tumor types, clinical profiles of available agents, strategies for managing treatment-related toxicities, and emerging data on novel agents that are being investigated. The webcast will feature 4 segments, each focusing on a different aspect of the management approach and each including a patient case vignette, brief presentations on key findings and patient counseling messages, and a panel discussion that summarizes key points and offers guidance on implementation of best practices in the clinic.

Benefits of Attending

  • Gain insight regarding the rationale and importance of HER2 testing in patients with breast, gastrointestinal, colorectal, and lung cancer
  • Learn from experts how to best manage treatment-related toxicities in patients on HER2-targeted therapy
  • Increase confidence in your ability to expertly counsel patients with breast, gastrointestinal, colorectal, and lung cancer who are receiving HER2-targeted agents about treatment adherence and AE management

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca and Daiichi-Sankyo, Inc.

Target Audience:

This educational program is directed toward all attendees of the 2021 Oncology Nursing Society (ONS) Annual Meeting, including nurses and other health care professionals with an interest in the treatment of cancer.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Explain the mechanistic rationale that informs the application of HER2-directed therapy in cancer care
  • Discuss recent safety and efficacy data pertaining to the use of HER2-directed therapies for the treatment of breast, lung, and gastrointestinal cancers
  • Devise strategies to promptly identify, mitigate, and manage treatment-related toxicities in patients with cancer being treated with HER2-directed therapies
  • Determine effective counseling strategies to assist patients’ understanding of the rationale for their cancer treatment plan and management of treatment-related toxicities


Ian Krop, MD, PhD
Ian Krop, MD, PhD
Associate Chief, Division of Breast Oncology
Senior Physician
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, MA
Elahe Salehi, NP
Elahe Salehi, NP
Director of Advanced Practice Nursing
Dana-Farber Cancer Institute
Boston, MA


2 Ways to Register
  1. Online: click here.
  2. Phone: Please call (888) 949-0045 or (609) 378-3701.
Physicians' Education Resource®
2 Clarke Drive
Suite 110
Cranbury, NJ 08512
Registration Fee - Free

For registration assistance, please email info@gotoper.com, or call (888) 949-0045 or (609) 378-3701.

Physicians' Education Resource®, LLC (PER®) fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please notify us in order to receive service. Please call (609) 378-3701.

Physicians' Education Resource®, LLC reserves the exclusive rights to all recordings or reproductions of the conference and supporting materials. Unauthorized recording, by any means, is expressly prohibited.  This includes, but is not limited to, recording of presentations or reproductions of supporting audio/visual materials, exhibits, and other supporting Continuing Education materials.

By attending a PER® conference, meeting or related activity ("Events"), all participants, attendees, exhibitors, sponsors, and guests ("you") create an agreement between you and PER® regarding the use and distribution of your image, including but not limited to your name, voice, and likeness ("Image"). By attending the Events, you acknowledge and agree that photographs, video, and/or audio recordings may be taken of you and you grant permission to PER® (and its agents) to utilize, in perpetuity, your Image in any electronic or print distribution, or by other means hereinafter created, both now and in the future, for any lawful purpose as determined by PER®.

Meeting information is accurate at the time of posting.

PER® complies with the Physician Payments Sunshine Act as a part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the ACA.


You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information

Registration Information

Professional Information


Calendar of Events
Filter By